-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

Benzinga·09/18/2025 11:59:20
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.